ClinicalTrials.gg
CompletedNCT07254325Updated Oct 21, 2026

Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers

A Phase 1 interventional study of Secukinumab 150mg s.c. in Psoriasis, sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd · Phase 1, Interventional, and Treatment

Updated Oct 21, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
30th of 54
114 · median 124
Started
2025
the only one that year
Phase 1
4 of 54
none open now
Registered
54th of 54
by date
Lead sponsor
2 of 54
Taizhou Mabtech Pharmaceutical Co.,Ltd

Among the 54 studies testing secukinumab in Psoriasis, this one is the 30th largest by enrollment, is the only one that started in 2025, is one of 4 in phase 1, and was the 54th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

This is a randomized, double-blinded, controlled Phase I study of new process CMAB015 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of new process CMAB015 versus Cosentyx(Secukinumab ) in healthy male subjects after a single dose.

Read the detailed description

This is a randomized, double-blind, parallel-controlled, single-dose phase I clinical study in healthy Chinese male subjects. A total of 114 subjects were planned to be enrolled and randomly assigned to the test group or the control group in a 1:1 ratio. Subjects in both groups received a single upper arm subcutaneous injection of new process CMAB015 or Cosentyx(Secukinumab) 150 mg, respectively. Subjects in both groups were observed for 112 days after administration to evaluate similarities in pharmacokinetics, safety, and immunogenicity.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male volunteers, age ranged 18 to 45 years (both inclusive);
  2. Subjects with body weight of ≥50 kg and ≤ 75 kg and ≥18 and \<26 kg/m2 ;
  3. Subjects and their partners were willing to use medically approved methods within 6 months of study administration, partners did not plan to become pregnant, subjects did not plan to donate sperm;
  4. The subjects have the ability to understand the full characteristics and objectives of the study, including the possible risks and side effects of the study; Moreover, the subjects can communicate well with researchers and complete the research according to the regulations;
  5. Subjects voluntarily sign ICF prior to the study.

Exclusion criteria

Exclusion Criteria:

  1. After comprehensive examination (vital signs, physical examination, , chest radiography, abdominal B-ultrasound, blood routine, urine routine, blood biochemistry, etc.), any examination item was judged abnormal by the investigator and had clinical significance;
  2. Patients with serious diseases such as cardiovascular system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematopoietic system, immune system, or any of the above diseases;
  3. Patients with currently active infected diseases;
  4. Subjects with past or current inflammatory bowel disease;
  5. History of malignant neoplasms within the last 5 years (other than completely resected basal cell or squamous cell carcinoma of the skin in situ);
  6. Any one of surface antigen, antibody, antibody, treponema pallidum antibody positive;
  7. Subjects with T-SPOT test positive. If the initial T-SPOT test result is inconclusive, a repeat test may be performed. If the result remains inconclusive or positive, the individual should be excluded;
  8. Those who smoked more than 5 cigarettes per day in the 6 months before screening and did not cooperate with smoking bans during the study period;
  9. Alcoholics,or participants who consumed more than 14 units of alcohol per week (1 unit = 17.7mL ethanol, i.e., 1 unit = 357mL 5% beer or 43mL 40% liquor or 147mL 12% wine) during the preceding 3 months were screened,or who have positive result in breath-test of alcohol or not willing to ban alcohol;
  10. Drug abusers, or drug users in the 3 months prior to screening, or excessive daily consumption of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250mL) in the 3 months prior to screening, or positive urine drug screening;
  11. Surgery within 4 weeks prior to screening; Or plan to have surgery during the study period;
  12. Use of any prescription drug, over-the-counter drug or health product within 4 weeks prior to screening, or prior use of such drug or health product within 5 half-lives, whichever is longer;
  13. Those who have used any biological agent, including , in the 3 months prior to screening, or who plan to receive live vaccine during the study period;
  14. Anti-il-17 antibody active ingredient, or latex allergy;
  15. Those with anti-IL-17 antibody and anti-drug antibody positive;
  16. Those who have been enrolled in other clinical studies or less than 3 months since the end of the most recent clinical study;
  17. Those who had lost blood or donated at least 400 mL in the 3 months prior to the trial, or had lost blood or donated at least 200 mL in the 1 month prior to screening, or planned to donate blood during the trial;
  18. Those who Can not tolerate venipunction, has a history of dizziness of needle and blood;
  19. Those who have special dietary requirements, or can not accept uniform diet;
  20. Other conditions considered inappropriate to be included in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Biosimilar Product

    new process CMAB015(Secukinumab ) 150 mg Subcutaneous injection in upper arm

    Biological: Secukinumab 150mg s.c.

  • Active comparator
    Reference Product

    Cosentyx(Secukinumab ) 150 mg Subcutaneous injection in upper arm

    Biological: Secukinumab 150mg s.c.

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time

    Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single injection of new process CMAB015/Cosentyx

    Time frame: up to 2688 hours

  2. Maximum Concentration of Secukinumab

    Maximum Concentration of Secukinumab After the Single Injection of new process CMAB015/Cosentyx

    Time frame: up to 2688 hours

Secondary outcomes

  1. Time to Maximum Concentration of Secukinumab

    Time to Maximum Concentration of Secukinumab after the Single Injection of new process CMAB015/Cosentyx

    Time frame: up to 2688 hours

  2. Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 2688 Hours

    Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 2688 Hours After the Single Injection of new process CMAB015/Cosentyx

    Time frame: up to 2688 hours

  3. Half time

    Half-time after the Single Injection of new process CMAB015/Cosentyx

    Time frame: up to 2688 hours

  4. Terminal phase elimination rate constant

    Terminal phase elimination rate constant after the Single Injection of new process CMAB015/Cosentyx

    Time frame: up to 2688 hours

  5. Clearance Clearance

    Clearance Rate after the Single Injection of new process CMAB015/Cosentyx

    Time frame: up to 2688 hours

  6. Apparent Volume of Distribution

    Terminal phase elimination rate constant after the Single Injection of new process CMAB015/Cosentyx

    Time frame: up to 2688 hours

  7. anti-drug antibodies(ADA)

    ADA Positive Rate after the Single Injection of new process CMAB015/Cosentyx

    Time frame: up to 2688 hours

  8. Neutralization antibodies(Nab)

    Neutralizing Antibody Positive Rate after the Single Injection of new process CMAB015/Cosentyx

    Time frame: up to 2688 hours

  9. Percentage of participants with Adverse Events

    Total Frequency of Adverse Events/Serious Adverse Events Within the Whole Time of the Study

    Time frame: up to 2688 hours

07

Study locations

1 site
  • Shanghai Jiaotong University School of Medicine
    Shanghai, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Jun 2026, 5 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 28, 2025
StartActual
Dec 15, 2025
Primary completionActual
Jun 12, 2026
CompletionActual
Jun 22, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 21, 2026
Primary completion
Jun 1, 2026→Jun 12, 2026 (actual)
Oct 21, 2026
Study completion
Jun 1, 2026→Jun 22, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Active, not recruiting→Completed
    Primary completion Jun 1, 2026→Jun 12, 2026 (now actual)
    Study completion Jun 1, 2026→Jun 22, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07254325
Lead sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Dec 15, 2025
Primary completion
Jun 12, 2026
Completion
Jun 22, 2026
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion